Cargando…

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

BACKGROUND: Systemic mastocytosis (SM) is a haematological disease characterised by organ infiltration by neoplastic mast cells. Almost all SM patients have a mutation in the gene encoding the tyrosine kinase receptor KIT causing a D816V substitution and autoactivation of the receptor. Mast cells an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grootens, Jennine, Ungerstedt, Johanna S., Ekoff, Maria, Rönnberg, Elin, Klimkowska, Monika, Amini, Rose-Marie, Arock, Michel, Söderlund, Stina, Mattsson, Mattias, Nilsson, Gunnar, Dahlin, Joakim S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557764/ https://www.ncbi.nlm.nih.gov/pubmed/30975542 http://dx.doi.org/10.1016/j.ebiom.2019.03.089

Ejemplares similares

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis
por: Lyberg, Katarina, et al.
Publicado: (2016)

CD203c distinguishes the erythroid and mast cell‐basophil differentiation trajectories among human FcεRI(+) bone marrow progenitors
por: Grootens, Jennine, et al.
Publicado: (2019)

Single-cell transcriptomics reveals the identity and regulators of human mast cell progenitors
por: Wu, Chenyan, et al.
Publicado: (2022)

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Divergent Effects of Acute and Prolonged Interleukin 33 Exposure on Mast Cell IgE-Mediated Functions
por: Rönnberg, Elin, et al.
Publicado: (2019)

Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience
por: Ungerstedt, Johanna, et al.
Publicado: (2022)

A new humanized in vivo model of KIT D816V(+) advanced systemic mastocytosis monitored using a secreted luciferase
por: Bibi, Siham, et al.
Publicado: (2016)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
por: Cao, Lihong, et al.
Publicado: (2023)

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
por: de Toledo, Marcelo A. S., et al.
Publicado: (2023)

Mast cells derived from systemic mastocytosis exhibit an increased responsiveness to hyperosmolarity
por: Lyberg, Katarina, et al.
Publicado: (2022)

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
por: Reszka, Edyta, et al.
Publicado: (2021)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder
por: Chatterjee, Anindya, et al.
Publicado: (2015)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis
por: Bandara, Geethani, et al.
Publicado: (2023)

Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material
por: Kähler, Christian, et al.
Publicado: (2007)

De novo Leukemic Variant of Mast Cell Leukemia With KIT D816V
por: Bang, Hae In, et al.
Publicado: (2015)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
por: Sandow, Lyndsey, et al.
Publicado: (2023)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

Localization-Specific Expression of CCR1 and CCR5 by Mast Cell Progenitors
por: Salomonsson, Maya, et al.
Publicado: (2020)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation
por: Rai, Shinya, et al.
Publicado: (2021)

Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation
por: Möller Westerberg, C, et al.
Publicado: (2012)

P1049: A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS
por: DeAngelo, D. J., et al.
Publicado: (2022)

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
por: Tobío, Araceli, et al.
Publicado: (2020)

Immunoprofiling Reveals Novel Mast Cell Receptors and the Continuous Nature of Human Lung Mast Cell Heterogeneity
por: Rönnberg, Elin, et al.
Publicado: (2022)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Mastitis Pathogens with High Virulence in a Mouse Model Produce a Distinct Cytokine Profile In Vivo
por: Johnzon, Carl-Fredrik, et al.
Publicado: (2016)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis
por: De Vita, Serena, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4p1bcvcvmth3v9dp9i8fpqvp58